Batch 001 - Live Allocation

Q4 launch pricing · ends 31 Dec

Vivre Labs

Institutional Longevity

Catalogue
Single-vial Blends · one injection
Clinical Details

- Peptides -

- Single-vial Blends -

- Goals -

- Clinical Reference -

- Guides -

- Integrity -

◇ Compound Reference

GROWTH HORMONE SUPPORTClinical EvidencePopular · GH-Axis Restoration

Sermorelin

GHRH Analog · 10mg

Status

Clinical Evidence

Route

SubQ

Half-life

~10-20 minutes plasma

Class

GHRH analog

MechanismGHRH Receptor Agonism

Cohort71 active prescriptions

Educational reference only - not a prescription or dosing recommendation. Some compounds are investigational or used off-label; suitability is a question for your own doctor. See Informed Consent & Disclaimer.

V-Series Member

$140 USD/vial

À-la-carte: $155 USD/vial · Save 10%

Vials per allocation

Member total (1×)$140

À-la-carte total$155

Flat per-vial pricing. International shipping $35, free on orders of $250 or more.

What this is

Established GHRH analog for endogenous GH pulse restoration. Studied in age-related GH decline.

GHRH Analog · 10mg per vial · lot-tested.

◇

Janoshik Verified

HPLC + MS purity, every batch

Independent third-party lab

⬡

COA Per Batch

Lot-level certificates published

Labeled vs actual mg disclosed

⊙

Lot-Tested

Every lot, independent lab

Report and verification code per lot

Sermorelin · Growth hormone support

◆ Certificate of Analysis · Sermorelin

JANOSHIK ANALYTICALHPLC + MS · Independent third-party

Lot testing in progress. The independent lab report for this Sermorelin lot will be published here, with its verification code, as soon as it is back.

◉

Clinical Overview

Sermorelin

Sermorelin is a 29-amino-acid synthetic GHRH analog representing the first 29 amino acids of native GHRH. Has the longest clinical history of any GH secretagogue, originally approved by the FDA in 1990 for pediatric GH deficiency (subsequently discontinued by manufacturer).

✦

Endogenous GH Release

GHRH-receptor agonism stimulating pulsatile pituitary GH.

❖

Feedback Preserved

Maintains the somatostatin negative-feedback loop.

◈

GH-Axis Support

Supports the growth-hormone axis physiologically.

◈

Mechanism

How It Works

GHRH receptor agonism. Stimulates endogenous growth hormone secretion through pulsatile pituitary activation.

Preserves the negative feedback loop with somatostatin.

Mechanism & evidence - the honest frame

Mechanism & evidence: Sermorelin is the 29-amino-acid N-terminal fragment of human GHRH (GHRH 1-29) and retains full GHRH activity - it binds pituitary GHRH receptors to stimulate the body’s own pulsatile GH release, rather than replacing GH. A key specificity point (Ishida et al., JCSM 2020): it raises GH without meaningful change in prolactin, LH, FSH, insulin, cortisol, glucose or thyroid hormone, and preserves natural feedback. Regulatory history is real - FDA-approved in 1997 for paediatric GH deficiency (Geref), since discontinued commercially. Honest frame: adult anti-aging / body-composition use is OFF-LABEL and not backed by large long-term trials; short plasma half-life (~11–12 min) means effect depends on the downstream GH pulse. As a GH-axis agent it falls under the same IGF-1 / oncological screening as the other secretagogues.

⊞

Technical Profile

Measurable Properties

Class	GHRH(1–29) analogue
Mechanism	GHRH-receptor agonism; stimulates endogenous GH - characterised
Terminal half-life	Short (~10–20 min); pharmacodynamic effect outlasts plasma presence
Metabolism	Rapid peptidase degradation
Evidence base	Moderate-to-strong; historically used diagnostically
Regulatory status	Research use only; not for self-administration

Certificate of Analysis (per batch)

Analytical method: UHPLC-MS. Batch COA available on request - link to be populated per shipment.

COA link - pending per batch

Mechanism well-characterised. Educational only; not a dosing instruction.

Clinical Literature

Peer-Reviewed References

Growth hormone secretagogues: history, mechanism of action, and clinical development

Ishida J, Saitoh M, Springer J, et al. · 2020 · JCSM Rapid Communications 2020;3(1):25–37

▾

Findings

Sermorelin is a 29-amino-acid analogue of human GHRH (GHRH 1-29) with full GHRH activity. Subcutaneous 2mg peaks in 5–20 min with a short half-life (~11–12 min); it stimulates pituitary GH WITHOUT significant change in prolactin, LH, FSH, insulin, cortisol, glucose, or thyroid hormone - preserving pulsatile secretion. FDA-approved 1997 for paediatric GH deficiency (Geref), since discontinued commercially.

View on publisher ↗

Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males

Sigalos JT, Pastuszak AW, et al. · 2020 · Translational Andrology and Urology (PMC7108996)

▾

Findings

Review: GH secretagogues can raise GH/IGF-1 toward levels seen with recombinant GH but with physiologic PULSATILE kinetics (vs persistent supra-therapeutic levels from exogenous GH), with comparable fat loss / lean mass gain and substantially less risk. Sermorelin shows a favourable safety profile (rare nausea, facial flushing, injection-site reactions); large longitudinal studies still needed.

View on publisher ↗

GHRH-analogue mechanism is well established and sermorelin has real regulatory history (paediatric GHD). Adult body-composition/anti-aging use is off-label and not supported by large long-term trials. Like all GH-axis agents, governed by Vivre oncological/IGF-1 screening (see gated GH-axis reference).

◇

Clinical Applications

Indications

Age-related GH decline
Adult GH deficiency
Sleep architecture support (GH peaks during slow-wave sleep)
Body composition support

⊙

Pharmacokinetics

Half-Life & Duration of Action

Half-life is how long a compound stays at active plasma concentration in your body. Most peptides in this catalogue have short plasma half-lives - they clear from your bloodstream within hours, sometimes minutes. The long-half-life compounds in this catalogue are the approved-class incretins (Tirzepatide, Semaglutide, Retatrutide), which are designed for once-weekly dosing - that's the molecular engineering choice that makes weekly dosing work.

Plasma Half-Life

~10-20 minutes plasma. Short discrete GHRH-receptor pulse; sermorelin is chosen over longer-acting GHRH analogs when shorter pulsatility is wanted.

Why this matters for you

If you don't tolerate a compound or need to discontinue a protocol, short-half-life peptides are out of your bloodstream within hours - not days or weeks. That said, the biological effects they initiate (tissue repair signalling, mitochondrial signalling, gene expression changes) often persist longer than the peptide itself, through downstream cellular cascades. This is normal peptide pharmacology and is important context - the molecule clears fast, but the biology takes longer to wind down.

Evidence Base

Long clinical history. Safety profile is well-established.

Dosing protocols, administration frequency, and titration schedules are not published on these public pages.

◎

Commonly Paired

Compounds Often Paired With Sermorelin

Clinical co-allocation patterns observed in Vivre's allocation history. Pairings are not prescriptions.

GHRP

Ipamorelin

Ghrelin Mimetic · 10mg

◆ GH amplification

Sermorelin (GHRH analog) paired with ipamorelin (selective ghrelin secretagogue) - pulse amplification through two complementary, non-competing pituitary pathways.

View Ipamorelin detail →

Growth Hormone Secretagogue

CJC-1295 (No DAC)

GHRH Analog · 10mg

◆ GHRH alternatives

Two GHRH analogs are not typically used at the same time; one or the other is chosen based on desired duration of action.

View CJC-1295 (No DAC) detail →

READY TO PROCEED

Start with the Biological Audit

Sermorelin is verified and lot-tested, dispensed following a Biological Audit. The Audit is complimentary for the Batch 001 cohort.

$140 USD/vial

Sermorelin · Member rate